Audrey L French1, Dara Grennan1, Elizabeth Daubert2, Eric C Seaberg3, Marion Peters4, Michael Augenbraun5, Margaret Fischl6, Seble Kassaye7, Ricardo Franco8, Mark Kuniholm9, Adaora A Adimora10, Kimberly Workowski11, Kathleen M Weber2. 1. Division of Infectious Diseases, Stroger Hospital of Cook County Heath. 2. Cook County Health and Hektoen Institute of Medicine, Chicago, Illinois. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Medicine, Northwestern University, Chicago, Illinois. 5. Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, New York. 6. Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida. 7. Division of Infectious Diseases, Georgetown University Medical Center, Washington, District of Columbia. 8. Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama. 9. Department of Epidemiology and Biostatistics, University at Albany, State University of New York, Rensselaer, New York. 10. Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 11. Department of Medicine, Emory University, Atlanta, Georgia, USA.
Abstract
OBJECTIVE: Eradication of hepatitis C virus (HCV) in HIV disease decreases liver and non-liver-related morbidity and mortality. Elevated markers of monocyte/macrophage activation (soluble CD163 and sCD14) are associated with excess non-AIDS morbidity and mortality in HIV. We examined the effect of HCV eradication on these markers in relation to change in hepatic fibrosis. DESIGN: A nested substudy within a longitudinal observational cohort. METHODS: We studied 126 HIV/HCV-coinfected women successfully treated for HCV, with undetectable HCV RNA at least 12 weeks after therapy completion. sCD163 and sCD14 were measured in serum collected before and after HCV eradication. Results were correlated with changes in markers of hepatic fibrosis. RESULTS: Mean age of participants was 56.3 years, mean CD4+ cell count was 615, and 72% had suppressed HIV RNA. After treatment, sCD163 and sCD14 levels significantly decreased from pre-treatment levels in unadjusted analyses. After adjusting for age, race, hepatic fibrosis status, baseline HCV RNA, CD4 count and HIV RNA status, cigarette smoking, and alcohol use, the decreases in sCD163 and sCD14 remained significant. Decrease in pre-treatment to post-treatment sCD163 were significantly positively correlated with changes in FIB-4 (r = 0.250, P = 0.005) and APRI (r = 0.262, P = 0.003); similarly decrease in sCD14 was significantly positively correlated with changes in FIB-4 (r = 0.333, P = 0.0001) and APRI (r = 0.457, P < 0.0001). CONCLUSION: HCV eradication is associated with significant reductions in monocyte/macrophage activation markers that correlate with reductions in markers of hepatic fibrosis. These findings support broad access to and early initiation of HCV treatment in order to decrease immune activation and improve health in HIV-infected persons.
OBJECTIVE: Eradication of hepatitis C virus (HCV) in HIV disease decreases liver and non-liver-related morbidity and mortality. Elevated markers of monocyte/macrophage activation (soluble CD163 and sCD14) are associated with excess non-AIDS morbidity and mortality in HIV. We examined the effect of HCV eradication on these markers in relation to change in hepatic fibrosis. DESIGN: A nested substudy within a longitudinal observational cohort. METHODS: We studied 126 HIV/HCV-coinfected women successfully treated for HCV, with undetectable HCV RNA at least 12 weeks after therapy completion. sCD163 and sCD14 were measured in serum collected before and after HCV eradication. Results were correlated with changes in markers of hepatic fibrosis. RESULTS: Mean age of participants was 56.3 years, mean CD4+ cell count was 615, and 72% had suppressed HIV RNA. After treatment, sCD163 and sCD14 levels significantly decreased from pre-treatment levels in unadjusted analyses. After adjusting for age, race, hepatic fibrosis status, baseline HCV RNA, CD4 count and HIV RNA status, cigarette smoking, and alcohol use, the decreases in sCD163 and sCD14 remained significant. Decrease in pre-treatment to post-treatment sCD163 were significantly positively correlated with changes in FIB-4 (r = 0.250, P = 0.005) and APRI (r = 0.262, P = 0.003); similarly decrease in sCD14 was significantly positively correlated with changes in FIB-4 (r = 0.333, P = 0.0001) and APRI (r = 0.457, P < 0.0001). CONCLUSION: HCV eradication is associated with significant reductions in monocyte/macrophage activation markers that correlate with reductions in markers of hepatic fibrosis. These findings support broad access to and early initiation of HCV treatment in order to decrease immune activation and improve health in HIV-infected persons.
Authors: Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Gregory D Huhn; Michael W Plankey; Marion Peters; Carl Grunfeld; Phyllis C Tien Journal: J Infect Dis Date: 2018-03-28 Impact factor: 5.226
Authors: Victoria Hernando; Santiago Perez-Cachafeiro; Charlotte Lewden; Juan Gonzalez; Ferran Segura; Jose Antonio Oteo; Rafael Rubio; David Dalmau; Santiago Moreno; Julia Del Amo Journal: J Hepatol Date: 2012-06-16 Impact factor: 25.083
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Suman Srinivasa; Kathleen V Fitch; Eva Petrow; Tricia H Burdo; Kenneth C Williams; Janet Lo; Hélène C F Cȏté; Steven K Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Juan Berenguer; Elena Rodríguez-Castellano; Ana Carrero; Miguel A Von Wichmann; Marta Montero; María J Galindo; Josep Mallolas; Manuel Crespo; María J Téllez; Carmen Quereda; José Sanz; Carlos Barros; Cristina Tural; Ignacio Santos; Federico Pulido; Josep M Guardiola; Rafael Rubio; Enrique Ortega; María L Montes; Juan J Jusdado; Gabriel Gaspar; Herminia Esteban; José M Bellón; Juan González-García Journal: Hepatology Date: 2017-06-22 Impact factor: 17.425
Authors: Victoria Cairoli; Elena De Matteo; Paola Casciato; Beatriz Ameigeiras; María Victoria Preciado; Pamela Valva Journal: PLoS One Date: 2022-07-07 Impact factor: 3.752